BXPHF (Botanix Pharmaceuticals) ROE % Adjusted to Book Value: -22.58% (As of Dec. 2025)


What is Botanix Pharmaceuticals ROE % Adjusted to Book Value?

Botanix Pharmaceuticals BXPHF ROE % Adjusted to Book Value is -22.58% as of Dec. 2025. The stock has 7 warning signs investors should review.

Botanix Pharmaceuticals's ROE % for the quarter that ended in Dec. 2025 was -99.34%. Botanix Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2025 was 4.40. Botanix Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -22.58%.

Botanix Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Botanix Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Botanix Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Botanix Pharmaceuticals ROE % Adjusted to Book Value Chart

Botanix Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.61 -13.63 -11.63 -3.51 -8.37

Botanix Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.33 -3.63 -5.98 -12.07 -22.58

BXPHF vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Botanix Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Botanix Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Botanix Pharmaceuticals's ROE % Adjusted to Book Value falls into.


Botanix Pharmaceuticals ROE % Adjusted to Book Value Calculation

Botanix Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-89.90% / 10.74
=-8.37%

Botanix Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-99.34% / 4.40
=-22.58%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -22.58% mean?
Botanix Pharmaceuticals (BXPHF) has a ROE % Adjusted to Book Value of -22.58% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Botanix Pharmaceuticals and its competitors.
Is Botanix Pharmaceuticals' ROE % Adjusted to Book Value too high?
Botanix Pharmaceuticals' current ROE % Adjusted to Book Value is -22.58%.
How does Botanix Pharmaceuticals' ROE % Adjusted to Book Value compare to VRTX and REGN?
Botanix Pharmaceuticals' ROE % Adjusted to Book Value of -22.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Botanix Pharmaceuticals and its competitors. Botanix Pharmaceuticals's current ROE % Adjusted to Book Value is -22.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Botanix Pharmaceuticals stock overvalued right now?
Botanix Pharmaceuticals (BXPHF) has a current ROE % Adjusted to Book Value of -22.58%. The current ROE % Adjusted to Book Value is -22.58%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Botanix Pharmaceuticals (BXPHF), the current ROE % Adjusted to Book Value is -22.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Botanix Pharmaceuticals Business Description

Other Exchanges BOT:Australia
Address 41 - 47 Colin Street, Suite 3, West Perth, WA, AUS, 6005
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.